桂林三金(002275.SZ)孫公司BC006單抗注射液獲臨牀試驗批准
格隆匯 3 月 21日丨桂林三金(002275.SZ)公吿,近日,桂林三金藥業股份有限公司(以下簡稱“公司”)控股孫公司寶船生物醫藥科技(上海)有限公司(以下簡稱“寶船生物”)收到國家藥品監督管理局核准簽發的BC006單抗注射液的臨牀試驗批件。
BC006單抗注射液是抗巨噬細胞集落刺激因子1受體(CSF-1R, Colony Stimulating Factor 1 Receptor)的人源化IgG1單克隆抗體,特異性靶向作用於單核-巨噬細胞系膜表面的CSF-1R,抑制其二聚化並阻斷下游細胞內信號通路活化,從而減少腫瘤微環境中免疫抑制性M2樣巨噬細胞數量,恢復巨噬細胞功能,產生抗腫瘤作用。BC006單抗注射液擬用於治療晚期惡性腫瘤,有望解決在多種實體瘤、血液腫瘤、骨關節疾病等疾病領域未能滿足的醫療需求。
寶船生物將盡快按照上述藥物臨牀批件要求開展臨牀研究。未來,公司將繼續加快推進寶船生物其他在研品種的研發,為公司進一步深化生物製藥戰略佈局和提高整體競爭力打下堅實的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.